Brilliant lecture by Michael Hofman on differences between PSMA tracers for diagnostics and therapy in #prostatecancer
1. PSMA11, DCFPyL or PSMA7 likely interchangeable
2. For therapy PSMA617 and I&T: likely radio equivalent
#APCCC24

Our editorial in European Urology on prostate radiotherapy for mHSPC is now online ! Chris Parker

Read here:
authors.elsevier.com/c/1i~y6_6tuN-i…

RM_Radiotherapy The Royal Marsden NHS Foundation Trust The ICR #prostatecancer

As long as the community, which often is medoncs discussing radiopharm, as ‘dose’ we are doomed to not make progress. Pains me this basic rad physics 101 terminology is not even known. Now nuc med, who 100% knows the difference, is saying ‘dose’ to over simplify, when they know…

Great comments by Daniel E Spratt on PSMA therapy
1. Should be treated as radiation treatment and not drug
2. Activity (not dose) should be adapted to tumor burden to ensure proper efficacy
3. Impact of fractionation needs to be studied
#APCCC24

Impact of neoadjuvant relugolix on patient-reported sexual function and bother. pubmed.ncbi.nlm.nih.gov/38665954/

Cristian Udovicich Sandy Srinivas GU Cast | Urology podcast! Sean Ong Peter Mac Radiation Oncology “Serious GU symptoms” in this context included prostate radiotherapy. Hardly surprising that giving prostate RT upfront reduces risk of subsequent prostate RT. Am I missing something?

After the OS ⬆️ of RT to the prostate in STAMPEDE Arm H for low volume metastatic PCa, should it now be SOC for both low and high volume after PEACE-1 demonstrated ⬇️ serious GU symptoms in the era of systemic intensification? Excellent presentation from Sandy Srinivas. #APCCC24 …

It’s a bit shocking but good to see mature salvage RT data. To me the good biochemical control rates emphasize need for ADT (at least short term)

Also with G3+ toxicity near 8% opens the concept of needing spacers and/or tighter margins (MRL or GU-Lok)

Looking Forward to Reviewing the Submissions!

Sean Collins Prostate SBRT@Georgetown University Selection bias by the investigators or the editors?🤔

Selection Bias?

Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Fol… pubmed.ncbi.nlm.nih.gov/38652872/

Sean Collins Prostate SBRT@Georgetown University In the trial, we did not allow for tamoxifen to be administered for prevention of gynecomastia for patients randomized to Darolutamide monotherapy. However, it will be interesting to see what the rates of gynecomastia are on Darolutamide monotherapy compared to ADT.

Vedang Murthy Sean Collins Prostate SBRT@Georgetown University Great question. 6-months of LHRHa plus bicalutamide is our institutional standard, and we wanted to test Darolutamide against maximal combined androgen blockade. However, agree that most institutions utilize a shorter duration of bicalutamide.

Great Question for Martin King, M.D. Ph.D. the Principle Investigator at Dana Farber
Martin King

Paul Sargos Vedang Murthy Sean Collins Prostate SBRT@Georgetown University GETUG Association Française d'Urologie - AFU Paul Nguyen Ploussard Guillaume Morgan Roupret ESTRO ASTRO European Association of Urology (EAU) SFRO I've used 0.2 for a number of years as a predictor - shifted to 0.1 post-icecap. My figures are ~92% reach 0.2 6 months post and ~85% reach 0.1. So it clearly parses cohort into reasonable blocks to explore de-escalation / escalation approaches from my perspective.

Vedang Murthy Sean Collins Prostate SBRT@Georgetown University Same phase 2 randomized trial from GETUG,Association Française d'Urologie - AFU.
'' DARIUS '' TRIAL, finished in few months.

✨Efficacy end point with PSA at M6.
✨Genomic and radiomics ancillary studies will be of interest!
✨Pooled data with INTREPID also...Paul Nguyen

Very important paper confirming surrogacy of cPFS and rPFS in mHSPC with OS. Great work. We need ICE!!! ⁦Michael Morris⁩ ⁦The PCCTC⁩ ⁦Christopher Sweeney, MBBS⁩

Great paper by Baris Turkbey MD and team. We encounter this problem not so rarely when reading PSMA PET/CT and I'm very glad to see this publication address this issue!

Congrats!